Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Those with co-occurring obesity or type 2 diabetes may be eligible for GLP-1 agonist therapy for these licensed indications, and any observed effects on alcohol consumption could be monitored and reported as part of ongoing research efforts
The body may adapt to the medication over time
The number of doses depends on the vial strength, dilution, and your chosen dose
Eli Lilly submitted it for FDA review in late 2025, with potential approval expected in early 2026
It cannot compensate for every cause of oxidative stress or poor health
US$ 23.98
US$ 28.43
US$ 24.42
US$ 20.60
